Psilera is at the forefront of developing innovative therapies for neurological conditions, particularly focusing on hard-to-treat disorders such as Frontotemporal Dementia (FTD). The company has established six distinct serotonergic compound families and boasts a proprietary library that encompasses over one million novel compounds. This extensive library is supported by a robust intellectual property portfolio, with 13 patents filed, including two issued by the USPTO, which cover a significant range of these compounds. Psilera's approach emphasizes patient-centric therapies, aiming to revolutionize small molecule drug discovery and provide new treatment options for conditions that currently lack effective therapies.

The leadership team at Psilera brings over 100 years of combined experience in the biotech and pharmaceutical sectors, contributing to the company's strategic direction and innovation. With a proven track record of generating substantial value—over $1.5 billion from previous ventures—the co-founders are well-positioned to drive Psilera's mission forward. The company is actively engaged in research and development, with positive preclinical data for its candidate PSIL-006, highlighting its commitment to advancing treatments for neurological disorders. As Psilera continues to expand its pipeline and explore new opportunities, it remains dedicated to enhancing the landscape of mindful medicine.

United States

Psilera is a scientist-owned, woman-co-founded biotechnology research company with offices in New Jersey & Florida. Founded in 2019 by Jackie von Salm & Chris Witowski, Psilera is focused on early-stage drug discovery & development to provide new neurological therapeutics to the world. Psilera’s team is a dynamic collective of individuals with expertise in Synthetic & Computational Chemistry, Clinical Development, Operations, Business Development, Strategy, and People.

Psilera

Company Details